In reaction to strong earnings/guidance:

ANSS +9.9%, ARII +9.8%, RIMM +9.3%, LOCM +8.7%, NTES +8.2%, BCSI +7.7%, ITRI +7.0%, NM +6.6%, OCNW +6.5%, FADV +6.5%, TEX +6.4%, SNPS +6.4%, IFSIA +6.0%, GA +5.9%, ADI +4.6%, RRR + 3.5%, TQNT +2.7%, PLLL +2.3%, KDN +1.9%, TRN +1.9%, VIV +1.7%, ACTL +1.3%, JCP +1.3%... M&A news: CPS +43.2% (to be acquired by Reed Elsevier for $50/share), PROS +24.5% (reaches agreement to merge with MIG, PROS shreholders to receive ~$20.00/share), FBN +16.1% (Sun Capital Partners proposes to acquire co at a substantial premium)... Other news: BNVI +18.1% (announces "positive developments" in on-going Phase 1/2 cancer drug trial), SQNM +5.2% (announces key milestone in development of noninvasive prenatal down syndrome test), CPST +4.5% (receives another order in the oil & gas market), IVAC +3.9% (receives orders for five 200 Lean magnetic disk sputtering systems for delivery in 2008), PQ +3.8% (will replace HH in S&P 600), FTEK +2.6% (announces two Fuel Chem orders)... Analyst upgrades: GFI +5.7% (upgraded to Buy at UBS), MDRX +3.9% (upgraded to Buy at UBS), ACH +3.6% (hearing added to Conviction Buy List at tier 1 firm), STC +3.5% (upgraded to Buy at Ferris Baker), GRMN +2.7% (upgraded to Outperform at Baird), ENR +2.5% (upgraded to Buy at Citigroup), CSCO +2.2% (upgraded to Buy at Citigroup), RIG +1.0% (hearing upgraded to Buy at tier 1 firm).